Switch theme
Sign up to access all valuation multiples
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
2015
52
LTM Revenue $6.0M
Last FY EBITDA -$66.5M
-$2.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bolt Biotherapeutics has a last 12-month revenue (LTM) of $6.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Bolt Biotherapeutics achieved revenue of $7.7M and an EBITDA of -$66.5M.
Bolt Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bolt Biotherapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.0M | XXX | $7.7M | XXX | XXX | XXX |
| Gross Profit | $6.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$66.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -864% | XXX | XXX | XXX |
| EBIT | -$65.0M | XXX | -$68.2M | XXX | XXX | XXX |
| EBIT Margin | -1079% | XXX | -887% | XXX | XXX | XXX |
| Net Profit | -$58.1M | XXX | -$63.1M | XXX | XXX | XXX |
| Net Margin | -965% | XXX | -821% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bolt Biotherapeutics's stock price is $0.
Bolt Biotherapeutics has current market cap of $12.1M, and EV of -$2.1M.
See Bolt Biotherapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$2.1M | $12.1M | XXX | XXX | XXX | XXX | $-1.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bolt Biotherapeutics has market cap of $12.1M and EV of -$2.1M.
Bolt Biotherapeutics's trades at -0.3x EV/Revenue multiple, and 0.0x EV/EBITDA.
Equity research analysts estimate Bolt Biotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bolt Biotherapeutics has a P/E ratio of -0.2x.
See valuation multiples for Bolt Biotherapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.1M | XXX | $12.1M | XXX | XXX | XXX |
| EV (current) | -$2.1M | XXX | -$2.1M | XXX | XXX | XXX |
| EV/Revenue | -0.3x | XXX | -0.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBIT | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/Gross Profit | -0.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBolt Biotherapeutics's last 12 month revenue growth is -36%
Bolt Biotherapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.5M for the same period.
Bolt Biotherapeutics's rule of 40 is -980% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bolt Biotherapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bolt Biotherapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -36% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -864% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -980% | XXX | -901% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 747% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 987% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bolt Biotherapeutics acquired XXX companies to date.
Last acquisition by Bolt Biotherapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Bolt Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bolt Biotherapeutics founded? | Bolt Biotherapeutics was founded in 2015. |
| Where is Bolt Biotherapeutics headquartered? | Bolt Biotherapeutics is headquartered in United States of America. |
| How many employees does Bolt Biotherapeutics have? | As of today, Bolt Biotherapeutics has 52 employees. |
| Who is the CEO of Bolt Biotherapeutics? | Bolt Biotherapeutics's CEO is Mr. William P. Quinn. |
| Is Bolt Biotherapeutics publicy listed? | Yes, Bolt Biotherapeutics is a public company listed on NAS. |
| What is the stock symbol of Bolt Biotherapeutics? | Bolt Biotherapeutics trades under BOLT ticker. |
| When did Bolt Biotherapeutics go public? | Bolt Biotherapeutics went public in 2021. |
| Who are competitors of Bolt Biotherapeutics? | Similar companies to Bolt Biotherapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Bolt Biotherapeutics? | Bolt Biotherapeutics's current market cap is $12.1M |
| What is the current revenue of Bolt Biotherapeutics? | Bolt Biotherapeutics's last 12 months revenue is $6.0M. |
| What is the current revenue growth of Bolt Biotherapeutics? | Bolt Biotherapeutics revenue growth (NTM/LTM) is -36%. |
| What is the current EV/Revenue multiple of Bolt Biotherapeutics? | Current revenue multiple of Bolt Biotherapeutics is -0.3x. |
| Is Bolt Biotherapeutics profitable? | Yes, Bolt Biotherapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
